close read more

Our 5 therapeutic areas

To discover new treatments that improve patients’ lives, Servier invests an average of 25% of
its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development
efforts in therapeutic areas where needs are substantial.

    Cardiovascular diseases

    16

    medicines available to health care
    professionals and patients

    6 th

    largest player worldwide
    and 2nd in Europe

    more than 17 million

    patients worldwide treated with
    a Servier medicine for a condition affecting
    the heart or blood vessels

    Cardiovascular diseases are the leading cause of mortality in the world and are responsible for 31% of deaths1 every year. Committed for more than 60 years to the treatment of these pathologies, Servier has acquired recognized expertise.

    More than 17 million patients worldwide are being treated with a Servier medicine for a condition affecting the heart or blood vessels. Servier continues to innovate in the field of heart failure: Omecamtiv mecarbil, a selective cardiac myosin activator developed in close collaboration with Amgen and Cytokinetics, is in phase III clinical evaluation.

    Servier also focuses its innovation efforts on developing Single Pill Combinations (SPC). By simplifying treatment, these SPCs increase treatment compliance.